Stay updated with breaking news from Area Approach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First-in-class treatment option reduces number and intensity of hot flashes and night sweats TOKYO, Dec. 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. today announced the European Commission on...
Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new pooled efficacy and safety analyses from the...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3b...